4.8 Article

Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay

期刊

FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.688436

关键词

SARS-CoV-2; COVID-19; T cell response; interferon gamma release assay (IGRA); high through put

资金

  1. Program for Advancement of Corona Research
  2. Bavarian Ministry for Science and Arts
  3. Bavarian State Ministry of Science and the Arts
  4. University Hospital
  5. LMU Munich
  6. Helmholtz Centre Munich
  7. University of Bonn
  8. University of Bielefeld
  9. German Ministry for Education and Research [01KI20271]
  10. Marie-Sklodowska-Curie Program Training Network for the Immunotherapy of Cancer and for Optimizing adoptive T cell therapy of cancer - H2020 Program of the European Union [641549, 955575]
  11. Hector foundation
  12. International Doctoral Program i Target
  13. Elite Network of Bavaria
  14. German Cancer Aid
  15. Ernst-Jung-Stiftung
  16. LMU Munich's Institutional Strategy LMUexcellent within the German Excellence Initiative
  17. Bundesministerium fur Bildung und Forschung Project Oncoattract and CONTRACT
  18. European Research Council, ARMOR-T [756017]
  19. German Research Foundation (DFG)
  20. Fritz-Bender-Foundation
  21. Bavarian Ministry of Economic affairs (m4 award)
  22. Jose-Carreras Foundation
  23. European Union's Horizon 2020 research and innovation programme, ORCHESTRA [101016167]
  24. European Research Council (ERC) [756017] Funding Source: European Research Council (ERC)

向作者/读者索取更多资源

Adaptive immune responses to structural proteins of the SARS-CoV-2 virus play a crucial role in protection against COVID-19. This study found that convalescent COVID-19 patients still exhibit broad T cell reactivity to multiple SARS-CoV-2 structural proteins over 200 days after infection. The study also showed a loose but significant correlation between anti-Nucleocapsid antibody titer and the magnitude and breadth of the T cell response.
Background: Adaptive immune responses to structural proteins of the virion play a crucial role in protection against coronavirus disease 2019 (COVID-19). We therefore studied T cell responses against multiple SARS-CoV-2 structural proteins in a large cohort using a simple, fast, and high-throughput approach. Methods: An automated interferon gamma release assay (IGRA) for the Nucleocapsid (NC)-, Membrane (M)-, Spike-C-terminus (SCT)-, and N-terminus-protein (SNT)-specific T cell responses was performed using fresh whole blood from study subjects with convalescent, confirmed COVID-19 (n = 177, more than 200 days post infection), exposed household members (n = 145), and unexposed controls (n = 85). SARS-CoV2-specific antibodies were assessed using Elecsys (R) Anti-SARS-CoV-2 (Ro-N-Ig) and Anti-SARS-CoV-2-ELISA (IgG) (EI-S1-IgG). Results: 156 of 177 (88%) previously PCR confirmed cases were still positive by Ro-N-Ig more than 200 days after infection. In T cells, most frequently the M-protein was targeted by 88% seropositive, PCR confirmed cases, followed by SCT (85%), NC (82%), and SNT (73%), whereas each of these antigens was recognized by less than 14% of non-exposed control subjects. Broad targeting of these structural virion proteins was characteristic of convalescent SARS-CoV-2 infection; 68% of all seropositive individuals targeted all four tested antigens. Indeed, anti-NC antibody titer correlated loosely, but significantly with the magnitude and breadth of the SARS-CoV-2-specific T cell response. Age, sex, and body mass index were comparable between the different groups. Conclusion: SARS-CoV-2 seropositivity correlates with broad T cell reactivity of the structural virus proteins at 200 days after infection and beyond. The SARS-CoV-2-IGRA can facilitate large scale determination of SARS-CoV-2-specific T cell responses with high accuracy against multiple targets.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据